GMED vs IONS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GMED exhibits a stable financial profile with a Piotroski F-Score of 4/9 and an exceptionally clean balance sheet characterized by a Debt/Equity ratio of 0.03. While the current price of $93.70 trades at a significant premium to its Graham Number ($54.65), it remains well below the growth-based intrinsic value of $115.64. The company demonstrates explosive earnings growth (437% YoY) and a consistent track record of beating analyst estimates over 25 quarters. Despite bearish insider sentiment and weak technical trends, the fundamental growth trajectory and liquidity position make it a strong long-term candidate.
IONS presents a significant disconnect between its market valuation and fundamental performance. While the Piotroski F-Score of 5/9 indicates stable financial health, the company is grappling with negative revenue growth (-10.30%) and a severe collapse in YoY EPS (-167.4%). Despite a massive 181% price surge over the last year, the valuation is extreme with a Price/Book of 25.10 and a Price/Sales of 13.16. Heavy insider selling by the CEO and CFO, combined with a bearish technical trend, suggests the current price is driven by speculative pipeline expectations rather than realized value.
Compare Another Pair
Related Comparisons
GMED vs IONS: Head-to-Head Comparison
This page compares Globus Medical, Inc. (GMED) and Ionis Pharmaceuticals, Inc. (IONS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.